The Companion Diagnostics for Oncology Market: Enabling Precision Medicine, Guiding Targeted Therapy Selection, and Integrating Diagnostic Testing with Pharmaceutical Drug Development

The Companion Diagnostics (CDx) for Oncology Market is experiencing robust and critical growth, serving as the linchpin for personalized medicine by identifying which patients are most likely to respond to a specific targeted therapeutic agent. The primary market catalyst is the continuous and accelerating discovery of novel biomarkers and genetic mutations (e.g., EGFR, ALK, HER2, PD-L1) in various cancers, for which pharmaceutical companies are developing highly selective, potent drugs. The discussion must emphasize the mandatory, symbiotic relationship between a CDx test and its corresponding drug; the FDA often requires the diagnostic to be approved simultaneously with the drug to ensure appropriate patient selection, making the CDx an integrated component of the drug's label and commercialization strategy. The high cost and significant side effects of many targeted cancer therapies necessitate…